Ceftobiprole
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antimicrobial Agent
Conditions
Antimicrobial Agent, Cephalosporins, Drug Resistance
Trial Timeline
Apr 1, 2009 → Jun 1, 2009
NCT ID
NCT00965042About Ceftobiprole
Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Antimicrobial Agent. The current trial status is completed. This product is registered under clinical trial identifier NCT00965042. Target conditions include Antimicrobial Agent, Cephalosporins, Drug Resistance.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00965042 | Phase 1 | Completed |
| NCT00771524 | Phase 1 | Completed |
| NCT00771719 | Phase 1 | Terminated |
| NCT01026740 | Phase 1 | Completed |
Competing Products
1 competing product in Antimicrobial Agent
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| daptomycin 6 mg/kg IV | Merck | Approved | 85 |